GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » Operating Income

Bio-Rad Laboratories (Bio-Rad Laboratories) Operating Income : $338 Mil (TTM As of Dec. 2023)


View and export this data going back to 1980. Start your Free Trial

What is Bio-Rad Laboratories Operating Income?

Bio-Rad Laboratories's Operating Income for the three months ended in Dec. 2023 was $95 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $338 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Bio-Rad Laboratories's Operating Income for the three months ended in Dec. 2023 was $95 Mil. Bio-Rad Laboratories's Revenue for the three months ended in Dec. 2023 was $681 Mil. Therefore, Bio-Rad Laboratories's Operating Margin % for the quarter that ended in Dec. 2023 was 13.99%.

Good Sign:

Bio-Rad Laboratories Inc operating margin is expanding. Margin expansion is usually a good sign.

Bio-Rad Laboratories's 5-Year average Growth Rate for Operating Margin % was 11.40% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 was 3.09%. Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 108.04%.


Bio-Rad Laboratories Operating Income Historical Data

The historical data trend for Bio-Rad Laboratories's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Operating Income Chart

Bio-Rad Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 229.66 421.33 500.34 475.12 337.80

Bio-Rad Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 111.17 61.91 89.62 90.95 95.32

Bio-Rad Laboratories Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $338 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bio-Rad Laboratories  (NYSE:BIO) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bio-Rad Laboratories's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=381.268 * ( 1 - 18.37% )/( (9766.167 + 10371.615)/ 2 )
=311.2290684/10068.891
=3.09 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=11895.943 - 370.783 - ( 1758.993 - max(0, 558.176 - 3146.77+1758.993))
=9766.167

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=12299.07 - 320.313 - ( 1607.142 - max(0, 522.799 - 3048.33+1607.142))
=10371.615

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Bio-Rad Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1763.012/( ( (711.402 + max(869.193, 0)) + (723.73 + max(959.254, 0)) )/ 2 )
=1763.012/( ( 1580.595 + 1682.984 )/ 2 )
=1763.012/1631.7895
=108.04 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(457.402 + 775.818 + 154.557) - (370.783 + 0 + 147.801)
=869.193

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(489.017 + 780.517 + 171.654) - (320.313 + 0 + 161.621)
=959.254

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Bio-Rad Laboratories's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=95.317/681.184
=13.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Bio-Rad Laboratories Operating Income Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Traded in Other Exchanges
Address
1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Executives
Tania Devilliers officer: INT PRIN ACCTG OFC C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen officer: EVP, Global Human Resources 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski officer: EVP, Global Supply Chain C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison director C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May officer: EVP, President, LSG C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last officer: EVP, Chief Operating Officer 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam officer: SVP, Chief Accounting Officer C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal officer: EVP, Chief Financial Officer 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst officer: EVP, General Counsel & Sec 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright officer: Executive Vice President C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley officer: EVP, GBL Commercial Operations 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz 10 percent owner 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz director, 10 percent owner
Norman D Schwartz director, 10 percent owner, officer: Chairman, President, and CEO 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547